31 results on '"Stölzel, Matthias"'
Search Results
2. A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilisation in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN)
3. Can We Identify Sources of Fine Particles Responsible for Exercise-Induced Ischemia on Days with Elevated Air Pollution? The ULTRA Study
4. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study
5. Workgroup Report: Workshop on Source Apportionment of Particulate Matter Health Effects-Intercomparison of Results and Implications
6. An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron‐Induced Cardiovascular Effects
7. Short-Term Mortality Rates during a Decade of Improved Air Quality in Erfurt, Germany
8. MIRABEGRON ADD-ON TREATMENT TO SOLIFENACIN IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS: A RESPONDER ANALYSIS OF A RANDOMIZED, DOUBLE BLIND, PHASE 3B STUDY: PD36-02
9. IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH MIRABEGRON ADD-ON TREATMENT IN A RANDOMIZED, DOUBLE-BLIND, PHASE 3B STUDY IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS WITH AN INADEQUATE RESPONSE TO SOLIFENACIN: PD36-01
10. Daily mortality and particulate matter in different size classes in Erfurt, Germany
11. PM source apportionment and health effects. 3. Investigation of inter-method variations in associations between estimated source contributions of PM2.5 and daily mortality in Phoenix, AZ
12. PM source apportionment and health effects: 1. Intercomparison of source apportionment results
13. Diverging long-term trends in ambient urban particle mass and number concentrations associated with emission changes caused by the German unification
14. Mirabegron as Add-on Treatment to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Solifenacin Monotherapy:Responder Analyses and Patient-Reported Outcomes from the BESIDE study
15. PD26-06 EFFICACY AND SAFETY OF MIRABEGRON ADD-ON THERAPY TO SOLIFENACIN IN OLDER PATIENT POPULATIONS WITH OVERACTIVE BLADDER
16. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)
17. PD36-01 IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH MIRABEGRON ADD-ON TREATMENT IN A RANDOMIZED, DOUBLE-BLIND, PHASE 3B STUDY IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS WITH AN INADEQUATE RESPONSE TO SOLIFENACIN
18. An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects.
19. A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
20. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy.
21. Source apportionment of ambient fine particle size distribution using positive matrix factorization in Erfurt, Germany
22. Semi Volatile Organic Compounds in Ambient PM2.5. Seasonal Trends and Daily Resolved Source Contributions
23. Daily mortality and particulate matter in different size classes in Erfurt, Germany
24. PM source apportionment and health effects. 3. Investigation of inter-method variations in associations between estimated source contributions of PM2.5 and daily mortality in Phoenix, AZ
25. PM source apportionment and health effects: 1. Intercomparison of source apportionment results
26. PARTICULATE MATTER IN SEVERAL SIZE CLASSES AND DAILY MORTALITY IN ERFURT, GERMANY
27. Semi Volatile Organic Compounds in Ambient PM2.5. Seasonal Trends and Daily Resolved Source Contributions.
28. PM source apportionment and health effects. 3. Investigation of inter-method variations in associations between estimated source contributions of PM2.5 and daily mortality in Phoenix, AZ.
29. Ambient source-specific particles are associated with prolonged repolarization and increased levels of inflammation in male coronary artery disease patients
30. A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the [beta]3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder.
31. The influence of improved air quality on mortality risks in Erfurt, Germany.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.